TW345575B - Pharmaceutical composition comprising an inhibitor for ras farnesylation and the preparation of the inhibitor compound - Google Patents

Pharmaceutical composition comprising an inhibitor for ras farnesylation and the preparation of the inhibitor compound

Info

Publication number
TW345575B
TW345575B TW085108987A TW85108987A TW345575B TW 345575 B TW345575 B TW 345575B TW 085108987 A TW085108987 A TW 085108987A TW 85108987 A TW85108987 A TW 85108987A TW 345575 B TW345575 B TW 345575B
Authority
TW
Taiwan
Prior art keywords
alkyl
inhibitor
alkenyl
pharmaceutical composition
nitro
Prior art date
Application number
TW085108987A
Other languages
English (en)
Inventor
Huw Davies David
Thomas Boyle Francis
Michael Wardleworth James
Wedderburn Kenny Peter
Beverley Scholes Peter
Stanley Matiusiak Zbigniew
Original Assignee
Zeneca Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zeneca Ltd filed Critical Zeneca Ltd
Application granted granted Critical
Publication of TW345575B publication Critical patent/TW345575B/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/12—Oxygen or sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pyrrole Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
TW085108987A 1995-08-04 1996-07-23 Pharmaceutical composition comprising an inhibitor for ras farnesylation and the preparation of the inhibitor compound TW345575B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB9515975.2A GB9515975D0 (en) 1995-08-04 1995-08-04 Chemical compounds

Publications (1)

Publication Number Publication Date
TW345575B true TW345575B (en) 1998-11-21

Family

ID=10778742

Family Applications (1)

Application Number Title Priority Date Filing Date
TW085108987A TW345575B (en) 1995-08-04 1996-07-23 Pharmaceutical composition comprising an inhibitor for ras farnesylation and the preparation of the inhibitor compound

Country Status (23)

Country Link
US (2) US6232338B1 (zh)
EP (1) EP0842151A1 (zh)
JP (1) JPH11510178A (zh)
KR (1) KR100502770B1 (zh)
CN (2) CN1101380C (zh)
AU (1) AU720353B2 (zh)
BR (1) BR9609701A (zh)
CA (1) CA2226671C (zh)
CZ (1) CZ293694B6 (zh)
GB (1) GB9515975D0 (zh)
HU (1) HUP9802857A3 (zh)
IL (1) IL123155A0 (zh)
MX (1) MX9800946A (zh)
MY (1) MY141457A (zh)
NO (2) NO316624B1 (zh)
NZ (1) NZ313696A (zh)
PL (1) PL190873B1 (zh)
RU (1) RU2191773C2 (zh)
SK (1) SK14598A3 (zh)
TR (2) TR199800147T1 (zh)
TW (1) TW345575B (zh)
WO (1) WO1997006138A1 (zh)
ZA (1) ZA966610B (zh)

Families Citing this family (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6310095B1 (en) 1995-11-06 2001-10-30 University Of Pittsburgh Inhibitors of protein isoprenyl transferases
US6204293B1 (en) 1995-11-06 2001-03-20 University Of Pittsburgh Inhibitors of protein isoprenyl transferases
US6693123B2 (en) 1995-11-06 2004-02-17 University Of Pittsburgh Inhibitors of protein isoprenyl transferases
US6221865B1 (en) 1995-11-06 2001-04-24 University Of Pittsburgh Inhibitors of protein isoprenyl transferases
WO1998007692A1 (en) * 1996-08-17 1998-02-26 Zeneca Limited 3-mercaptopyrrolidines as farnesyl protein transferase inhibitors
CA2288330C (en) 1997-05-07 2014-02-11 University Of Pittsburgh Benzoyl amino acid derivatives useful as inhibitors of protein isoprenyl tranferases
JP2001520222A (ja) 1997-10-22 2001-10-30 ゼネカ・リミテッド イミダゾール誘導体およびファルネシルタンパク質トランスフェラーゼインヒビターとしてのそれらの使用
DK1025088T3 (da) 1997-10-22 2001-11-12 Astrazeneca Ab Imidazolderivater og deres anvendelse som farnesylproteintransferaseinhibitorer
WO1999041235A1 (en) * 1998-02-10 1999-08-19 Astrazeneca Uk Limited Farnesyl transferase inhibitors
GB9930317D0 (en) * 1999-12-22 2000-02-09 Zeneca Ltd Novel compounds
GB9930318D0 (en) 1999-12-22 2000-02-09 Zeneca Ltd Novel compounds
US6924276B2 (en) 2001-09-10 2005-08-02 Warner-Lambert Company Diacid-substituted heteroaryl derivatives as matrix metalloproteinase inhibitors
ITRM20020016A1 (it) * 2002-01-15 2003-07-15 Sigma Tau Ind Farmaceuti Derivati di acidi fenil(alchil)carbossilici e derivati fenilalchileterociclici dionici, loro uso come medicamenti ad attivita' ipoglicemizza
US7132100B2 (en) 2002-06-14 2006-11-07 Medimmune, Inc. Stabilized liquid anti-RSV antibody formulations
US7425618B2 (en) 2002-06-14 2008-09-16 Medimmune, Inc. Stabilized anti-respiratory syncytial virus (RSV) antibody formulations
EP1539234A4 (en) * 2002-09-05 2006-02-15 Medimmune Inc METHODS OF PREVENTING OR TREATING CELLULAR MALIGNITES BY ADMINISTERING CD2 ANTAGONISTS
US8034831B2 (en) * 2002-11-06 2011-10-11 Celgene Corporation Methods for the treatment and management of myeloproliferative diseases using 4-(amino)-2-(2,6-Dioxo(3-piperidyl)-isoindoline-1,3-dione in combination with other therapies
US7563810B2 (en) * 2002-11-06 2009-07-21 Celgene Corporation Methods of using 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione for the treatment and management of myeloproliferative diseases
EP2316487B1 (en) 2003-04-11 2014-06-11 MedImmune, LLC Recombinant IL-9 antibodies & uses thereof
JP4934426B2 (ja) 2003-08-18 2012-05-16 メディミューン，エルエルシー 抗体のヒト化
US20060228350A1 (en) * 2003-08-18 2006-10-12 Medimmune, Inc. Framework-shuffling of antibodies
EP1667991B1 (en) 2003-09-16 2008-05-14 Astrazeneca AB Quinazoline derivatives as tyrosine kinase inhibitors
WO2005089515A2 (en) * 2004-03-18 2005-09-29 The Brigham And Women's Hospital, Inc. Methods for the treatment of synucleinopathies
WO2005089502A2 (en) * 2004-03-18 2005-09-29 The Brigham And Women's Hospital, Inc. Methods for the treatment of synucleinopathies
WO2005089504A2 (en) * 2004-03-18 2005-09-29 The Brigham And Women's Hospital, Inc. Methods for the treatment of synucleinopathies
US20070293539A1 (en) * 2004-03-18 2007-12-20 Lansbury Peter T Methods for the treatment of synucleinopathies
WO2005089496A2 (en) * 2004-03-18 2005-09-29 The Brigham And Women's Hospital, Inc. Methods for the treatment of synucleinopathies
EP2422811A2 (en) 2004-10-27 2012-02-29 MedImmune, LLC Modulation of antibody specificity by tailoring the affinity to cognate antigens
JP5153613B2 (ja) 2005-03-18 2013-02-27 メディミューン，エルエルシー 抗体のフレームワーク・シャッフル
KR20080025174A (ko) 2005-06-23 2008-03-19 메디뮨 인코포레이티드 응집 및 단편화 프로파일이 최적화된 항체 제제
WO2007092285A2 (en) * 2006-02-02 2007-08-16 Link Medicine Corporation Treatment of synucleinopathies
JP5209625B2 (ja) 2006-08-28 2013-06-12 協和発酵キリン株式会社 アンタゴニストのヒトｌｉｇｈｔ特異的ヒトモノクローナル抗体
AU2008232902B2 (en) 2007-03-30 2013-10-03 Medlmmune, Llc Antibody formulation
CN101376656A (zh) * 2007-08-30 2009-03-04 山东轩竹医药科技有限公司 培南衍生物
KR101686247B1 (ko) 2007-10-31 2016-12-14 메디뮨 엘엘씨 단백질 스캐폴드
US8232402B2 (en) * 2008-03-12 2012-07-31 Link Medicine Corporation Quinolinone farnesyl transferase inhibitors for the treatment of synucleinopathies and other indications
EP2370436A1 (en) * 2008-11-13 2011-10-05 Link Medicine Corporation Azaquinolinone derivatives and uses thereof
US20110060005A1 (en) * 2008-11-13 2011-03-10 Link Medicine Corporation Treatment of mitochondrial disorders using a farnesyl transferase inhibitor
US20100331363A1 (en) * 2008-11-13 2010-12-30 Link Medicine Corporation Treatment of mitochondrial disorders using a farnesyl transferase inhibitor
JP2012520884A (ja) 2009-03-18 2012-09-10 ザ ボード オブ トラスティーズ オブ ザ リランド スタンフォード ジュニア ユニバーシティー フラビウイルス科ウイルス感染症を治療する方法および組成物
DK2668210T3 (da) 2011-01-26 2020-08-24 Celldex Therapeutics Inc Anti-kit antistoffer og anvendelser deraf
US9250552B2 (en) * 2011-03-30 2016-02-02 Canon Kabushiki Kaisha Polymerizable monomer, polymeric compound, charge control agent containing the polymeric compound, and developer bearing member and toner which contain the charge control agent
CN116574185A (zh) 2012-07-25 2023-08-11 塞尔德克斯医疗公司 抗kit抗体及其用途
CA2887129A1 (en) 2012-10-09 2014-04-17 Igenica, Inc. Anti-c16orf54 antibodies and methods of use thereof
SG11201509982UA (zh) 2013-06-06 2016-04-28 Igenica Biotherapeutics Inc
DK3041507T3 (da) 2013-08-26 2021-07-26 Biontech Res And Development Inc Nukleinsyrer, der koder for humane antistoffer mod sialyl-lewis a
GB201403775D0 (en) 2014-03-04 2014-04-16 Kymab Ltd Antibodies, uses & methods
KR102614642B1 (ko) 2014-06-04 2023-12-19 바이오엔테크 리서치 앤드 디벨롭먼트 인코포레이티드 강글리오사이드 ｇｄ２에 대한 사람 단클론 항체
PT3333191T (pt) 2014-12-11 2020-12-15 Pf Medicament Anticorpos anti-c10orf54 e suas utilizações
BR112017015880A2 (pt) 2015-03-03 2018-07-31 Kymab Ltd anticorpos, usos e métodos
EP3319938B1 (en) * 2015-07-10 2022-04-06 University of Maryland, Baltimore Small molecule inhibitors of the mcl-1 oncoprotein and uses thereof
EP3909983A1 (en) 2015-12-02 2021-11-17 STCube & Co. Inc. Antibodies and molecules that immunospecifically bind to btn1a1 and the therapeutic uses thereof
KR20180100122A (ko) 2015-12-02 2018-09-07 주식회사 에스티사이언스 당화된 btla(b- 및 t-림프구 약화인자)에 특이적인 항체
EP3534947A1 (en) 2016-11-03 2019-09-11 Kymab Limited Antibodies, combinations comprising antibodies, biomarkers, uses & methods
CN111051346A (zh) 2017-05-31 2020-04-21 斯特库伯株式会社 使用免疫特异性结合btn1a1的抗体和分子治疗癌症的方法
KR20200015602A (ko) 2017-05-31 2020-02-12 주식회사 에스티큐브앤컴퍼니 Btn1a1에 면역특이적으로 결합하는 항체 및 분자 및 이의 치료적 용도
EP3635007A1 (en) 2017-06-06 2020-04-15 STCube & Co., Inc. Methods of treating cancer using antibodies and molecules that bind to btn1a1 or btn1a1-ligands
US11707522B2 (en) 2017-10-13 2023-07-25 Boehringer Ingelheim International Gmbh Human antibodies to Tn antigen
EP3824287A1 (en) 2018-07-20 2021-05-26 Pierre Fabre Médicament Receptor for vista
GB201908453D0 (en) * 2019-06-12 2019-07-24 Enterprise Therapeutics Ltd Compounds for treating respiratory disease

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1283906C (en) 1983-05-09 1991-05-07 Makoto Sunagawa .beta.-LACTAM COMPOUNDS AND PRODUCTION THEREOF
JPS60233076A (ja) 1984-05-03 1985-11-19 Sumitomo Chem Co Ltd 新規なβ−ラクタム化合物およびその製造法
DE3579888D1 (de) 1984-11-08 1990-10-31 Sumitomo Pharma Carbapenemverbindungen und deren herstellung.
KR880006244A (ko) 1986-11-24 1988-07-22 후지사와 도모 기찌 로 3-피롤리디닐티오-1-아자바이스클로[3.2.0]햅트2-엔-2-카르복실산 화합물 및 이의 제조방법
GB8921635D0 (en) 1989-09-25 1989-11-08 Fujisawa Pharmaceutical Co 3-pyrrolidinylthio-1-azabicyclo(3.2.0)hept-2-ene-2-carboxylic acid derivatives
CA2036163C (en) 1990-02-14 2001-06-19 Makoto Sunagawa Novel beta-lactam compounds and their production
IE910606A1 (en) 1990-02-23 1991-08-28 Sankyo Co Carbapenem derivatives having antibiotic activity, their¹preparation and their use
GB9107363D0 (en) 1991-04-08 1991-05-22 Ici Plc Antibiotic compounds
US6083917A (en) * 1990-04-18 2000-07-04 Board Of Regents, The University Of Texas System Methods and compositions for the identification, characterization and inhibition of farnesyltransferase
US5185248A (en) 1990-05-08 1993-02-09 E. R. Squibb & Sons, Inc. Farnesyl-protein transferase assay for identifying compounds that block neoplastic transformation
JPH0578360A (ja) 1991-01-31 1993-03-30 Banyu Pharmaceut Co Ltd ２−［２−（スルフアモイルアルキル）ピロリジニルチオカルバペネム誘導体
GB9107341D0 (en) 1991-04-08 1991-05-22 Ici Plc Antibiotic compounds
GB9107342D0 (en) 1991-04-08 1991-05-22 Ici Plc Antibiotic compounds
RU2093514C1 (ru) 1991-06-04 1997-10-20 Санкио Компани Лимитед Производные 1-метилкарбапенема и способ их получения
JPH04368386A (ja) 1991-06-18 1992-12-21 Sankyo Co Ltd １−メチルカルバペネム−３−カルボン酸の製造法
US5360798A (en) 1991-07-04 1994-11-01 Shionogi Seiyaku Kabushiki Kaisha Aminooxypyrrolidinylthiocarbapenem compounds
DK0537007T3 (da) 1991-10-11 1995-09-25 Squibb & Sons Inc Anvendelse af farnesyl-protein-transferase-inhibitorer til fremstilling af et lægemiddel til blokering af neoplastisk transformation af celler fremkaldt af ras-oncogener
JPH05239058A (ja) 1991-12-17 1993-09-17 Fujisawa Pharmaceut Co Ltd ３−ピロリジニルチオ−１−アザビシクロ［３．２．０ヘプト−２−エン−２−カルボン酸化合物
GB9202298D0 (en) 1992-02-04 1992-03-18 Ici Plc Antibiotic compounds
CZ290002B6 (cs) 1992-03-11 2002-05-15 Sankyo Company Limited Antimikrobiální karbapenemové deriváty, způsob výroby a farmaceutický prostředek
CA2091309A1 (en) 1992-03-26 1993-09-27 Frederic H. Jung Antibiotic compounds
GB9304156D0 (en) 1992-03-26 1993-04-21 Zeneca Ltd Antibiotic compounds
WO1993021186A1 (en) 1992-04-13 1993-10-28 Fujisawa Pharmaceutical Co., Ltd. Substituted 3-pyrrolidinylthio-carbapenems as antimicrobial agents
EP0581501B1 (en) 1992-07-21 1998-09-09 Zeneca Limited Antibiotic carbapenem compounds
CA2099818A1 (en) 1992-07-21 1994-01-22 Frederic H. Jung Antibiotic compounds
EP0581502B1 (en) 1992-07-21 1998-10-21 Zeneca Limited Antibiotic carbapenem compounds
EP0590885B1 (en) 1992-09-28 2000-03-15 Zeneca Limited Antibiotic carbapenem compounds
CA2106330A1 (en) 1992-10-07 1994-04-08 Patrice J. Siret Antibiotic compounds
CA2118985A1 (en) 1993-04-02 1994-10-03 Dinesh V. Patel Heterocyclic inhibitors of farnesyl protein transferase
CA2165176A1 (en) 1993-06-18 1995-01-05 Samuel L. Graham Inhibitors of farnesyl-protein transferase
US5468733A (en) * 1993-09-30 1995-11-21 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
US5576293A (en) * 1993-09-30 1996-11-19 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
CN1151156A (zh) 1994-03-15 1997-06-04 卫材株式会社 异戊二烯基转移酶抑制剂
CA2155448A1 (en) * 1994-08-11 1996-02-12 Katerina Leftheris Inhibitors of farnesyl protein transferase
US5571835A (en) * 1994-09-29 1996-11-05 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
ES2196163T3 (es) 1995-07-31 2003-12-16 Shionogi & Co Derivados de pirrolidina con una actividad de inhibicion de la fosfolipasa a2.
JP3115285B2 (ja) 1999-04-27 2000-12-04 徳光 中ノ瀬 合成樹脂体を利用した水上施設

Also Published As

Publication number Publication date
CN1197453A (zh) 1998-10-28
TR200101884T2 (tr) 2002-06-21
IL123155A0 (en) 1998-09-24
CZ293694B6 (cs) 2004-07-14
KR100502770B1 (ko) 2007-03-15
CN1101380C (zh) 2003-02-12
MX9800946A (es) 1998-04-30
MY141457A (en) 2010-04-30
NO980467L (no) 1998-04-03
RU2191773C2 (ru) 2002-10-27
TR199800147T1 (xx) 1998-04-21
HUP9802857A3 (en) 1999-05-28
KR19990036110A (ko) 1999-05-25
PL190873B1 (pl) 2006-02-28
PL324819A1 (en) 1998-06-22
BR9609701A (pt) 1999-03-23
WO1997006138A1 (en) 1997-02-20
US6541491B1 (en) 2003-04-01
AU6622396A (en) 1997-03-05
AU720353B2 (en) 2000-06-01
NO20024950D0 (no) 2002-10-15
NO316624B1 (no) 2004-03-15
NO980467D0 (no) 1998-02-03
JPH11510178A (ja) 1999-09-07
CA2226671A1 (en) 1997-02-20
NZ313696A (en) 2000-01-28
GB9515975D0 (en) 1995-10-04
CA2226671C (en) 2005-04-05
NO20024950L (no) 1998-04-03
CN1377647A (zh) 2002-11-06
HUP9802857A2 (hu) 1999-04-28
SK14598A3 (en) 1998-09-09
EP0842151A1 (en) 1998-05-20
US6232338B1 (en) 2001-05-15
CZ30998A3 (cs) 1998-06-17
ZA966610B (en) 1997-02-04

Similar Documents

Publication Publication Date Title
TW345575B (en) Pharmaceutical composition comprising an inhibitor for ras farnesylation and the preparation of the inhibitor compound
IL107884A0 (en) Sulphonamides, their manufacture and pharmaceutical compositions containing them
RU2088589C1 (en) Derivatives of 17 beta-substituted-4-aza-5-5 alpha-androstane-3-ones, methods of synthesis of compounds, pharmaceutical composition, compound 4
UA39093C2 (uk) Похідні пептидів, що є інгібіторами еластази лейкоцитів людини, спосіб їх отримання та фармацевтична композиція
NL300175I2 (nl) Methylsulfonylfenyl-2-(5H)-furanonen als remmers van COX-2.
AP9701041A0 (en) Pyridylpyrrole compounds.
DE69738815D1 (de) Verwendung von Cyclooxygenase-2 Inhibitoren zur Behandlung und Vorbeugung von Neoplasia
DK0790986T3 (da) Anilinderivater
DE69523169D1 (de) Verwendung von Mangiferin oder seinen Derivaten zur kosmetischen Anwendung
ATE260658T1 (de) Pharmazeutische zubereitungen zur verminderung von atmungsdepressionen
ATE227293T1 (de) 2,3-disubstituierte-(5,6)-heteroarylkondensiert - pyrimidin-4-one
DE69713273D1 (de) Verwendung von 3,4-Diphenylchromanen zur Herstellung eines Arzneimittels zur Behandlung bzw. Vorbeugung des Prostatakarzinoms
NO960632L (no) Nye bis-naftalimider for behandling av kreft
DE69418744D1 (de) Verwendung von Pregnanderivaten zur Behandlung von Tumoren
HK1014011A1 (en) Cyclopeptolides
DK0823909T3 (da) Hidtil ukendte heterocykliske forbindelser
GR3029489T3 (en) Use of leflunomid for the inhibition of interleukin 8.
NO933241L (no) Aminosyrer nyttige ved terapi av osteoartikulaere paavirkninger
GB9116056D0 (en) Compounds
ATE100102T1 (de) Substituierte derivate von 20,21dinoreburnamenin, verfahren zur herstellung und so hergestellte zwischenprodukte, ihre verwendung als arzneimittel und diese enthaltende pharmazeutische zusammenstellungen.
DE68902627D1 (de) Verwendung von chromanderivaten zur herstellung eines medikamentes zur behandlung von depressiven zustaenden.
ES2062214T3 (es) Derivados de aminooligohidroxi inhibidores de renina.
DE69827706D1 (de) 5-(Heteroaryl)alkyl)-3-oxo-pyrido(1,2-a)benzimidazol-4-carboxamid (PBI) Derivate zur Behandlung von Störungen des zentralen Nervensystems
ATE168697T1 (de) Pyrrolidinderivate zur behandlung von cck und gastrin-abhängigen erkrankungen
GR3029492T3 (en) Use of leflunomid for the inhibition of interleukin 1 alpha.